Abstract
This perspective describes cardiovascular compounds dropped from clinical development in 2005 and is the first in a series of papers to be published in Expert Opinion on Investigational Drugs, discussing discontinued drugs from that year. Discontinued candidates are described by the phase of development they reached, based on the information available from the Pharmaprojects database. Discontinued drugs in the atherosclerosis/dyslipidaemia area are discussed in more detail.